Denmark's Nycomed has announced plans to cut 10% of its workforce as it begins to integrate the operations of recently-acquired German drugmaker Altana Pharma.
Chief executive Hakan Bjorklund said that as a result of the patent expiry of the firm's largest product, the gastrointestinal drug pantoprazole, "and current dynamics within the global pharmaceutical industry," the combined group will need to move with the times and " this will require profound change in all parts of our organisation. Regrettably this is not possible without a reduction of up to 1,250 jobs worldwide.
"Specifically, 200 positions will go at " central functions" in Germany and Denmark and 585 will be lost in R&D, while worldwide sales organisations will be affected by 465 redundancies, the vast majority of them in the 14 countries (Austria, Belgium, the Czech Republic, France, Germany, Greece, Hungary, Italy, Netherlands, Poland, Romania, Spain, Switzerland and the UK) with overlapping operations.
Germany will be hardest hit with the loss of 930 jobs, with the biggest impact taking place in Konstanz, the former headquarters of Altana Pharma, where 790 posts will go.
Source: PharmaTimes
No comments:
Post a Comment